Wondering if Recursion Pharmaceuticals at around US$4.67 a share is priced for its potential or still misunderstood by the ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Cathie Wood’s ARK ETF published their daily trades for Friday, December 19th, 2025, showcasing significant activity in several key stocks. Leading the trades was a substantial sale of 23,110 shares of ...

Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...

Investing.com - JPMorgan upgraded Recursion Pharmaceuticals (NASDAQ:RXRX) from Neutral to Overweight on Wednesday, while raising its price target to $11.00 from $10.00. The stock currently trades at ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

The trend of AI researchers developing new, small open source generative models that outperform far larger, proprietary peers continued this week with yet another staggering advancement. The goal is ...